Duration of DAPT in ACS: The DUAL-ACS Trial

Reported from ESC Congress 2025

Ali Nazmi Calik interviews David Newby on the landmark DUAL-ACS trial results he presented at ESC Congress 2025 in Madrid.

The trial compared 3 months versus 12 months of dual antiplatelet therapy (DAPT) after myocardial infarction in an all-comer population. Findings suggest that shorter therapy may offer better survival and reduced bleeding without increasing the risk of recurrent MI. These results could reshape future guidelines on post-MI care.